摘要
三阴性乳腺癌(TNBC)是指雌激素受体(ER)、孕激素受体(PR)和表皮生长因子受体2(HER-2)均为阴性的乳腺癌,以发病年龄轻、易早期发生转移为特点。TNBC对ER、PR为靶点的内分泌治疗和以HER-2为靶点的靶向药物治疗无效,已成为乳腺癌治疗的难点与研究的热点。为改进TNBC的临床诊断与治疗手段,学者们做了大量的研究来寻找更多新的生物标记物。笔者对近年来国内外关于TNBC的生物标记物研究进展进行综述。
Triple-negative breast cancer（TNBC） is a subtype of breast cancer defined as the absence of estrogen receptor（ER）, progesterone receptor（PR） and human epidermal growth factor receptor 2（HER-2）, and characterized by onset at a younger age and high incidence of early metastasis. TNBC does not respond to endocrine therapy targeting ER or PR and HER-2-targeted agents, and has accordingly become a challenge in clinical treatment and a hotspot in research of breast cancer. A great number of investigations have been done by scholars for finding new biomarkers of TNBC and thereby improving its clinical diagnosis and treatment. Here, the authors present the recent progress on researches concerning the biomarkers of TNBC both at home and abroad.
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2017年第11期1472-1477,共6页
China Journal of General Surgery
基金
湖南省科技计划基金资助项目(2015SK2017-2)
中南大学硕士研究生自主探索创新基金资助项目(2016zzts531)
关键词
三阴性乳腺癌
生物标记
肿瘤
综述文献
Triple Negative Breast Neoplasms
Biomarkers, Tumor
Review
